medigraphic.com
Instituto Nacional de Salud Pública

2024, Número 1

<< Anterior Siguiente >>

salud publica mex 2024; 66 (1)


Vacunas profilácticas contra el cáncer: desarrollo y desafíos en vacunas contra VHB y VPH en Latinoamérica

Ramírez-López LX, Carnalla-Cortés M, Barrientos-Gutiérrez T, Coursaget P, Muñoz N

Idioma: Ingles.
Referencias bibliográficas: 65
Paginas: 95-103
Archivo PDF: 281.51 Kb.


RESUMEN

Las vacunas contra el virus de la hepatitis B (VHB) y el virus del papiloma humano (VPH) son dos vacunas seguras y altamente efectivas que se desarrollaron a finales del siglo XX y pueden prevenir el cáncer humano. La vacuna contra el VHB previene el cáncer de hígado y la VPH previene el cáncer de cuello uterino y otros cánceres relacionados con el VPH. A partir de la identificación del inmunógeno, fueron necesarios 15 años para llegar a la producción industrial de la vacuna contra la hepatitis B y 20 años para las vacunas contra el VPH. Sin embargo, aunque las vacunas contra el VHB han estado disponibles comercialmente durante más de 40 años y se utilizan en la mayoría de los países, aún existen desafíos importantes para lograr la inmunización infantil universal contra la hepatitis B. De manera similar, las vacunas contra el VPH han estado disponibles comercialmente durante 17 años; sin embargo, en países con incidencias altas de cáncer de cuello uterino, todavía existen tasas bajas de vacunación contra el VPH. Se describe el desarrollo de las vacunas contra el VHB y el VPH, y se discuten los desafíos para lograr un acceso equitativo a estas vacunas en América Latina.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, et al.Hepatitis B virus infection in children and adolescents in a hyperendemicarea: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001;135(9):796-800. https://doi.org/10.7326/0003-4819-135-9-200111060-00009

  2. Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, Dinubile MJ, et al.Impact and effectiveness of the quadrivalent human papillomavirus vaccine:a systematic review of 10 years of real-world experience. Clin Infect Dis.2016;63(4):519-27. https://doi.org/10.1093/CID/CIW354

  3. Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnick AI.A serum antigen (Australia antigen) in Down’s syndrome, leukemia,and hepatitis. Ann Intern Med. 1967;66(5):924-31. https://doi.org/10.7326/0003-4819-66-5-924

  4. Trichopoulos D, Gerety RJ, Sparros L, Tabor E, Xirouchaki E, Muñoz N,et al. Hepatitis B and primary hepatocellular carcinoma in a europeanpopulation. Lancet. 1978;312(8102):1217-19. https://doi.org/10.1016/S0140-6736(78)92097-4

  5. Maupas P, Larouzé B, London WT, Werner B, Millman I, O’Connell A, etal. Antibody to hepatitis-B core antigen in patients with primary hepaticcarcinoma. Lancet. 1975;306(7923):9-11. https://doi.org/10.1016/S0140-

  6. 6736(75)92951-76. World Health Organization, International Agency for Research onCancer. Monographs on the evaluation of carcinogenic risks to humans.Lyon: WHO/IARC, 1994 [cited Apr 1, 2023]. Available from: https://monographs.iarc.who.int/wp-content/uploads/2018/06/mono77.pdf

  7. Maupas P, Coursaget P, Goudeau A, Drucker J, Bagros P. Immunizationagainst hepatitis B in man. Lancet. 1976;307(7974):1367-70. https://doi.org/10.1016/S0140-6736(76)93023-3

  8. Maupas P, Goudeau A, Coursaget P, Drucker J, Bagros P. Hepatitis Bvaccine: efficacy in high-risk settings, a two-year study. Intervirology.1978;10(3):196-208. https://doi.org/10.1159/000148983

  9. Maupas P, Barin F, Chiron JP, Coursaget P, Goudeau A, Perrin J, et al.Efficacy of hepatitis B vaccine in prevention of early HBsAg carrierstate in children. Controlled trial in an endemic area (Senegal). Lancet.1981;317(8215):289-92. https://doi.org/10.1016/S0140-6736(81)91908-5

  10. Chiron JP, Coursaget P, Yvonnet B, Auger F, Lee-Quan T, Barin F, et al.Simultaneous administration of hepatitis B and diphtheria/tetanus/poliovaccines. Lancet. 1984;323(8377):623-4. https://doi.org/10.1016/S0140-6736(84)91015-8

  11. Coursaget P, Leboulleux D, Soumare M, le Cann P, Yvonnet B, ChironJP, et al. Twelve-year follow-up study of hepatitis B immunization ofSenegalese infants. J Hepatol. 1994;21(2):250-4. https://doi.org/10.1016/S0168-8278(05)80404-0

  12. Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. Synthesis andassembly of hepatitis B virus surface antigen particles in yeast. Nature.1982;298:347-50. https://doi.org/10.1038/298347a0

  13. Michel ML, Pontisso P, Sobczak E, Malpièce Y, Streeck RE, TiollaisP. Synthesis in animal cells of hepatitis B surface antigen particlescarrying a receptor for polymerized human serum albumin. PNAS USA.1984;81(24):7708-12. https://doi.org/10.1073/PNAS.81.24.7708

  14. André FE. Overview of a 5-year clinical experience with a yeastderivedhepatitis B vaccine. Vaccine. 1990;8(Suppl 1):S74-8. https://doi.org/10.1016/0264-410X(90)90222-8

  15. Davidson M, Krugman S. Immunogenicity of recombinant yeasthepatitis B vaccine. Lancet. 1985;325(8420):108-9. https://doi.org/10.1016/S0140-6736(85)92000-8

  16. Stevens CE, Taylor PE, Tong MJ, Toy PT, Vyas GN, Nair PV, et al.Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immuneglobulin in prevention of perinatal hepatitis B virus transmission. JAMA.1987;257(19):2612-6. https://doi.org/10.1001/JAMA.257.19.2612

  17. World Health Organization. List of Prequalified Vaccines. WHO, 2023[cited Apr 8, 2023]. Available from: https://extranet.who.int/pqweb/vaccines/list-prequalified-vaccines

  18. World Health Organization, International Agency for Research onCancer. Liver cancer. France: WHO/IARC, 2022 [cited Mar 22, 2023].Available from: https://www.iarc.who.int/cancer-type/liver-cancer/

  19. Lo KJ, Tsai YT, Lee SD, Wu TC, Wang JY, Chen GH, et al.Immunoprophylaxis of infection with hepatitis B virus in infants bornto hepatitis B surface antigen-positive carrier mothers. J Infect Dis.1985;152(4):817-22. https://doi.org/10.1093/INFDIS/152.4.817

  20. Chang MH, You SL, Chen CJ, Liu CJ, Lai MW, Wu TC, et al. Longtermeffects of hepatitis B immunization of infants in preventing livercancer. Gastroenterology. 2016;151(3):472-80. https://doi.org/10.1053/J.GASTRO.2016.05.048

  21. Li RC, Yang JY, Gong J, Li YP, Huang ZN, Fang KX, et al. Efficacy ofhepatitis B vaccination on hepatitis B prevention and on hepatocellularcarcinoma. Chin J Epidemiol. 2004;25(5):385-7.

  22. Lee MS, Kim DH, Kim H, Lee HS, Kim CY, Park TS, et al. Hepatitis Bvaccination and reduced risk of primary liver cancer among male adults:a cohort study in Korea. Int J Epidemiol. 1998;27(2):316-9. https://doi.org/10.1093/IJE/27.2.316

  23. McMahon BJ, Bulkow LR, Singleton RJ, Williams J, Snowball M,Homan C, et al. Elimination of hepatocellular carcinoma and acutehepatitis B in children 25 years after a hepatitis B newborn and catchupimmunization program. Hepatology. 2011;54(3):801-7. https://doi.org/10.1002/HEP.24442

  24. Hall AJ, Inskip HM, Loik F, Day NE, O’Conor G, Bosch X, et al. TheGambia Hepatitis Intervention Study. Cancer Res. 1987;47(21):5782-7.

  25. Fortuin M, Chotard J, Jack AD, Maine NP, Mendy M, Hall AJ, et al.Efficacy of hepatitis B vaccine in the Gambian expanded programmeon immunisation. Lancet. 1993;341(8853):1129-32. https://doi.org/10.1016/0140-6736(93)93137-P

  26. Whittle H, Jaffar S, Wansbrough M, Mendy M, Dumpis U, Collinson A, etal. Observational study of vaccine efficacy 14 years after trial of hepatitisB vaccination in Gambian children. BMJ. 2002;325(7364):569-72. https://doi.org/10.1136/BMJ.325.7364.569

  27. Sheena BS, Hiebert L, Han H, Ippolito H, Abbasi-Kangevari M, Abbasi-Kangevari Z, et al. Global, regional, and national burden of hepatitis B,1990-2019: a systematic analysis for the Global Burden of Disease Study2019. Lancet Gastroenterol Hepatol. 2022;7(9):796-829. https://doi.org/10.1016/S2468-1253(22)00124-8

  28. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, etal. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidenceand Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer JClin. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660

  29. World Health Organization, International Agency for Research onCancer. Data visualization tools for exploring the global cancer burden in2020. WHO/IARC, 2020 [cited mar 22, 2023]. Available from: https://gco.iarc.fr/today/home

  30. World Health Organization. Immunization coverage. WHO, 2021 [citedMar 23, 2023]. Available from: https://www.who.int/en/news-room/factsheets/detail/immunization-coverage

  31. Das S, Ramakrishnan K, Behera SK, Ganesapandian M, Xavier AS,Selvarajan S. Hepatitis B vaccine and immunoglobulin: key concepts.J Clin Transl Hepatol. 2019;7(2):165-71. https://doi.org/10.14218/JCTH.2018.00037

  32. Durst M, Gissmann L, Ikenberg H, Zur-Hausen H. A papillomavirusDNA from a cervical carcinoma and its prevalence in cancer biopsysamples from different geographic regions. PNAS USA. 1983;80(12):3812-5. https://doi.org/10.1073/PNAS.80.12.3812

  33. Muñoz N, Bosch FX, de Sanjose S, Tafur L, Izarzugaza I, Gili M, et al. Thecausal link between human papillomavirus and invasive cervical cancer: apopulation-based case-control study in Colombia and Spain. Int J Cancer.1992;52(5):743-9. https://doi.org/10.1002/IJC.2910520513

  34. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV,et al. Epidemiologic classification of human papillomavirus types associatedwith cervical cancer. N Engl J Med. 2003;348(6):518-27. https://doi.org/10.1056/NEJMOA021641

  35. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, ShahKV, et al. Human papillomavirus is a necessary cause of invasive cervicalcancer worldwide. J Pathol. 1999;189(1):12-9. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F

  36. Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernández-Ávila M,Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18vaccine on all HPV-associated genital diseases in young women. JNCI.2010;102(5):325-39. https://doi.org/10.1093/JNCI/DJP534

  37. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1major capsid protein self-assembles into virus-like particles that are highlyimmunogenic. PNAS USA. 1992;89(24):12180-4. https://doi.org/10.1073/PNAS.89.24.12180

  38. Rose RC, Bonnez W, Reichman RC, Garcea RL. Expression of humanpapillomavirus type 11 L1 protein in insect cells: in vivo and in vitroassembly of viruslike particles. J Virol. 1993;67(4):1936-44. https://doi.org/10.1128/JVI.67.4.1936-1944.1993

  39. Kirnbauer R, Taub J, Greenstone H, Roden R, Dürst M, GissmannL, et al. Efficient self-assembly of human papillomavirus type 16 L1 andL1-L2 into virus-like particles. J Virol. 1993;67(12):6929-36. https://doi.org/10.1128/JVI.67.12.6929-6936.1993

  40. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, etal. Systemic immunization with papillomavirus L1 protein completelyprevents the development of viral mucosal papillomas. PNAS USA.1995;92(25):11553-7. https://doi.org/10.1073/PNAS.92.25.11553

  41. Muñoz N, Crawford L, Coursaget P. HPV vaccines for cervicalneoplasia. Lancet. 1995;345(8944):1-249.

  42. Dull P. Leadership. Deputy Director, Vaccine Development &Surveillance-Clinical Evaluation and HPV. Bill & Melinda Gates Foundation,2023 [cited Apr 28, 2023]. Available from: https://www.gatesfoundation.org/about/leadership/peter-dull

  43. Paavonen J, Garland SM, Jenkins D. Clinical trials of humanpapillomavirus vaccines. In: Human Papillomavirus: Proving and Using aViral Cause for Cancer. Academic Press Inc Elsevier Science. 2020:299-325. https://doi.org/10.1016/B978-0-12-814457-2.00019-2

  44. Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, et al. HPVVaccination and the Risk of Invasive Cervical Cancer. N Engl J Med.2020;383(14):1340-8. https://doi.org/10.1056/NEJMOA1917338

  45. De Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden ofcancer attributable to HPV by site, country and HPV type. Int J Cancer.2017;141(4):664-70. https://doi.org/10.1002/ijc.30716

  46. Piñeros M, Laversanne M, Barrios E, Cancela M de C, de Vries E,Pardo C, et al. An updated profile of the cancer burden, patterns andtrends in Latin America and the Caribbean. Lancet Reg Heal - Am.2022;13(100294):1-14. https://doi.org/10.1016/J.LANA.2022.100294

  47. Organización Panamericana de la Salud, Organización Mundial dela Salud. 59.o Consejo Directivo. 73.a Sesión del Comité Regional dela OMS para las Américas. Aumento de la capacidad de producción demedicamentos y tecnologías sanitarias esenciales. OPS/OMS, 2021 [citedApr 14, 2023]. Available from: https://www.paho.org/es/cuerpos-directivos/consejo-directivo/59o-consejo-directivo

  48. Cortés M de los A, Cardoso D, Fitzgerald J, Di Fabio JL. Public vaccinemanufacturing capacity in the Latin American and Caribbean region:Current status and perspectives. Biologicals. 2012;40(1):3-14. https://doi.org/10.1016/J.BIOLOGICALS.2011.09.013

  49. Instituto Butantan. Protal do Butantan. Vacina HPV. 2023 [cited Mar 19,2023]. Available from: https://butantan.gov.br/hpv#o-que-e-hpv

  50. World Health Organization. Human papillomavirus vaccines: WHOposition paper, December 2022. WHO, 2022 [cited Apr 14, 2023].Available from: https://www.who.int/teams/immunization-vaccines-andbiologicals/policies/position-papers/human-papillomavirus-(hpv)

  51. World Health Organization. Strategic Advisory Group of Experts(SAGE) on Immunization Evidence to recommendations framework 1.WHO, 2022 [cited Mar 18, 2023]. Available from: http://www.decidecollaboration.eu/WP5/Strategies/Framework

  52. World Health Organization. WHO updates recommendations onHPV vaccination schedule. WHO, 2022 [cited Jul 18, 2023]. Availablefrom: https://www.who.int/news/item/20-12-2022-WHO-updatesrecommendations-on-HPV-vaccination-schedule

  53. De Oliveira LH, Janusz CB, Da Costa MT, El Omeiri N, Bloem P, LewisM, et al. HPV vaccine introduction in the Americas: a decade of progressand lessons learned. Expert Rev Vaccines. 2022;21(11):1569-80. https://doi.org/10.1080/14760584.2022.2125383

  54. Enokida T, Moreira A, Bhardwaj N. Vaccines for immunopreventionof cancer. J Clin Invest. 2021;131(9):e146956. https://doi.org/10.1172/JCI146956

  55. Bonjour M, Charvat H, Franco EL, Piñeros M, Clifford GM, Bray F, etal. Global estimates of expected and preventable cervical cancers amonggirls born between 2005 and 2014: a birth cohort analysis. Lancet PublicHeal. 2021;6(7):e510-21. https://doi.org/10.1016/S2468-2667(21)00046-3

  56. Groopman JD, Smith JW, Rivera-Andrade A, Álvarez CS, Kroker-LobosMF, Egner PA, et al. Aflatoxin and the etiology of liver cancer and itsimplications for Guatemala. World Mycotoxin J. 2021;14(3):305-17. https://doi.org/10.3920/WMJ2020.2641

  57. Constable C, Caplan A. Comparison of the implementation of humanpapillomavirus and hepatitis B vaccination programs in the United States:Implications for future vaccines. Vaccine. 2020;38(5):954-62. https://doi.org/10.1016/J.VACCINE.2019.11.073

  58. Ropero-Álvarez AM, Vilajeliu A, Magariños M, Jauregui B, Guzmán L,Whittembury A, et al. Enablers and barriers of maternal and neonatalimmunization programs in Latin America. Vaccine. 2021;39(Suppl. 2):B34-43. https://doi.org/10.1016/j.vaccine.2020.07.051

  59. Bairwa M, Pilania M, Rajput M, Khanna P, Kumar N, Nagar M, etal. Pentavalent vaccine: A major breakthrough in India’s UniversalImmunization Program. Hum Vaccin Immunother. 2012;8(9):1314-6.https://doi.org/10.4161/HV.20651

  60. Drolet M, Bénard É, Pérez N, Brisson M, Ali H, Boily MC, et al.Population-level impact and herd effects following the introduction ofhuman papillomavirus vaccination programmes: updated systematicreview and meta-analysis. Lancet. 2019;394(10197):497-509. https://doi.org/10.1016/S0140-6736(19)30298-3

  61. Centers for Disease Control and Prevention. HPV Vaccine. HumanPapillomavirus (HPV). CDC, 2021 [cited Jan 22, 2023]. Available from:https://www.cdc.gov/hpv/parents/vaccine-for-hpv.html

  62. Kane MA, Stanley M. Pre-school HPV Immunization? The newsletteron HPV. 2022 [cited Apr 10, 2023]. Available from: https://www.hpvworld.com/articles/pre-school-hpv-immunization/

  63. Mouchet J, Salvo F, Raschi E, Poluzzi E, Antonazzo IC, De Ponti F, et al.Human papillomavirus vaccine and demyelinating diseases-A systematicreview and meta-analysis. Pharmacol Res. 2018;132:108-18. https://doi.org/10.1016/J.PHRS.2018.04.007

  64. World Health Organization. Global health sector strategy on viralhepatitis 2016-2021. Towards ending viral hepatitis. Geneva: WHO,2016 [cited Apr 8, 2023]. Available from: https://apps.who.int/iris/handle/10665/246177

  65. World Health Organization. Global strategy to accelerate theelimination of cervical cancer as a public health problem. Geneva:WHO, 2020 [cited Apr 8, 2023]. Available from: https://www.who.int/publications/i/item/9789240014107




2020     |     www.medigraphic.com